Loss of Raf Kinase Inhibitor Protein Promotes Cell Proliferation and Migration of Human Hepatoma Cells

Gastroenterology

Volumn 131, Issue 4, 2006, Pages 1208-1217

  Lee, Han Chu ^a   Tian, Bo ^a   Sedivy, John M ^b   Wands, Jack R ^a   Kim, Miran ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RNA; SOMATOMEDIN C;

ARTICLE; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 33749319933     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.07.012     Document Type: Article

References (55)

1. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 suppl (2004) S5-S16
2. Moradpour D., and Blum H.E. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 17 (2005) 477-483
3. Fausto N., Laird A., and Webber E. Role of growth factors and cytokines in hepatic regeneration. FASEB J 9 (1995) 1527-1536
4. Park Y.N., Chae K.J., Kim Y.B., Park P., and Theise N. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer 92 (2001) 2733-2738
5. Tannapfel A., and Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch 440 (2002) 345-352
6. Thorgeirsson S.S., Teramoto T., and Factor V.M. Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 18 (1998) 115-122
7. Humbel R.E. Insulin-like growth factors I and II. Eur J Biochem 190 (1990) 445-462
8. Scharf J., and Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 35 (2003) 685-693
9. Alexia C., Fallot G., Lasfer M., Schweizer-Groyer G., and Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells againist drug-induced apoptosis. Biochem Pharmacol 68 (2004) 1003-1015
10. Radcliff K., Tang T.B., Lim J., Zhang Z., Abedin M., Demer L.L., and Tintut Y. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 96 (2004) 398-400
11. Wang Y., and Sun Y. Insluin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2 (2002) 191-207
12. Nottage M., and Siu L.L. Rationale for Ras and Raf-kinase as a target for cancer theapeutics. Curr Pharm Design 8 (2003) 2231-2242
13. O'Neill E., and Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 90 (2004) 283-288
14. Chang F., Steelman L., Lee J., Shelton J., Navolanic P., Blalock W., Franklin R., and McCubrey J. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17 (2003) 1263-1293
15. Mitsui H., Takuwa N., Maruyama T., Maekawa H., Hirayama M., Sawatari T., Hashimoto N., Takuwa Y., and Kimura S. The MEK1-ERK MAP kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 92 (2001) 55-62
16. Schmidt C.M., McKillop I.H., Cahill P.A., and Sitzmann J.V. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236 (1997) 54-58
17. Schmidt C.M., McKillop I.M., Cahill P.A., and Sitzmann J.V. The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro. Eu J Gastroenterol Hepatol 1 (1999) 1393-1399
18. Dent P., and Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 7 (2001) 775-783
19. Weinstein-Oppenheimer C.R., Henriquez-Roldan C.F., Davis J.M., Navolanic P., Saleh O.A., Steelman L., Franklin R., Robinson P.J., McMahon M., and McCubrey J. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 7 (2001) 2898-2907
20. Keller E.T., Fu Z., and Brennan M. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68 (2004) 1049-1053
21. Odabaei G., Chatterjee D., Jazirehi A.R., Goodglick L., Yeung K.C., and Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91 (2004) 169-200
22. Schuierer M.M., Bataille F., Hagan S., Kolch W., and Bosserhoff A.K. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64 (2004) 5186-5192
23. Trakul N., and Rosner M.R. Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein. Cell Res 15 (2005) 19-23
24. Yeung K.C., Janosch P., McFerran B., Rose D.W., Mischak H., Sedivy J.M., and Kolch W. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein. Mol Cell Biol 20 (2000) 3079-3085
25. Yeung K.C., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fe F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M., and Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP. Nature 401 (1999) 173-177
26. Banfield M.J., Barker J.J., Perry A.C., and Brady R.L. Function from structure? The crystal structure of human phosphatidylethanolamine-binding protein suggests a role in membrane signal transduction. Structure 6 (1998) 1245-1254
27. Serre L., Pereira de Jesus K., Zelwer C., Bureaud N., Schoentgen F., and Benedetti H. Crystal structures of YBHB and YBCL form Escherichia coli, two bacterial homologues to a Raf kinase inhibitor protein. J Mol Biol 310 (2001) 617-634
28. Chatterjee D., Bai Y., Wang Z., Beach S., Mott S., Roy R., Braastad C., Sun Y., Mukhopadhyay A., Aggarwai B.B., Darnowski J., Pantazis P., Wyche J., Fu Z., Kitagwa Y., Keller E.T., Sedivy J.M., and Yeung K.C. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279 (2004) 17515-17523
29. Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Tao Z., and Keller E.T. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Nat Cancer Inst 95 (2003) 878-889
30. Zhang L., Fu Z., Binkley C., Giordano T., Burant C.F., Logsdon C.D., and Simeone D.M. Raf kinase inhibitory protein inhibits β-cell proliferation. Surgery 136 (2004) 708-715
31. Keller E.T. Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). Anticancer Drugs 15 (2004) 663-669
32. Keller E.T., Fu Z., and Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94 (2005) 273-278
33. Kauffman E.C., Robinson V.L., Stadler W.M., Sokoloff M.H., and Rinker-Schaeffer C.W. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 169 (2003) 1122-1133
34. Merle P., de la Monte S., Kim M., Herrmann M., Tanaka S., von dem Bussche A., Kew M.C., Trepo C., and Wands J.W. Functional consequences of Frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 127 (2004) 1110-1122
35. de la Monte S.M., Lahousse S.A., Carter J., and Wands J.R. ATP luminescence-based motility-invasion assay. Biotechniques 33 (2002) 98-100
36. Darlington G., Kelly J., and Buffone G. Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. In Vitro Cell Dev Biol 23 (1987) 349-354
37. He L., Isselbacher K.J., Wands J.R., Goodman H.M., Shih C., and Quaroni A. Establishment and characterization of a new human hepatocellular carcinoma cell line. In Vitro 20 (1984) 493-504
38. Knowles B., Howe C., and Aden D. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209 (1980) 497-499
39. Khamzina L., Gruppuso P., and Wands J.R. Insulin signaling through IRS-1 and IRS-2 in normal liver development. Gastroenterology 125 (2003) 572-585
40. Sasaki Y., Nishiyama Z.X., Avruch M., and Wands J.R. Expression and phosphorylation of insulin receptor substrate 1 during rat liver regeneration. J Biol Chem 268 (1993) 3805-3808
41. Ito T., Sasaki Y., and Wands J.R. Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinase. Mol Cell Biol 16 (1996) 943-951
42. Tanaka S., Ito T., and Wands J.R. Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules. J Biol Chem 271 (1996) 14610-14616
43. Tanaka S., Mohr L., Schmidt E.V., Sugimachi K., and Wands J.W. Biologic effects of human insulin receptor substrate-overexpression in hepatocytes. Hepatology 27 (1997) 598-604
44. Wands J.R., and Maradpour D.W. Molecular pathogenesis of hepatocellular carcinoma. In: Zakim D., and Boyer T.D. (Eds). Hepatology: a textbook of liver disease. 5th ed. (2006), Saunders, Philadelphia, PA 165-175
45. Tanaka S., and Wands J.R. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 98 (1997) 2100-2108
46. xL expression. Oncogene 23 (2004) 4993-5003
47. Alexia C., Lasfer M., and Groyer A. Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis. Evidence for heterogeneity of tumor cell lines. Ann N Y Acad Sci 1030 (2004) 219-229
48. Ito Y., Sasaki Y., Horimoto M., Wada S., Tanaka Y., Kasahara A., Ueki T., Hirano T., Yamamoto H., Fujimoto J., Okamoto E., Hayashi N., and Hori M. Activation of mitogen-activated protein kinases/extracellular signal-regulated in human hepatocellular carcinoma. Hepatology 27 (1998) 951-958
49. Mishima K., Yamada E., Masui K., Shimokawara T., Takayama K., Sugimura M., and Ichijima K. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma. Mod Pathol 11 (1998) 886-891
50. Price D.T., Rocca G.D., Guo C., Ballo M.S., Schwinn D.A., and Luttrell L.M. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162 (1999) 1537-1542
51. Sivaraman V.S., Wang H., Nuovo G.J., and Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99 (1997) 1478-1483
52. Tsuboi Y., Ichida T., Sugitani S., Genda T., Inayoshi J., Takamura M., Matsuda Y., Nomoto M., and Aoyagi Y. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 24 (2004) 432-436
53. Vicent S., Garayoa M., Lopez-Picazo J.M., Lozano M.D., Toled G., Thunnissen F.B., Manzano R.G., and Montuenga L.M. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 10 (2004) 3639-3649
54. Wada A., Fukui K., Sawai Y., Imanaka K., Kiso S., Tamura S., Shimomura I., and Hayashi N. Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J Hepatol 44 (2006) 142-150
55. Hong T., and Grabel L.B. Migration of F9 parietal endoderm cells is regulated by the ERK pathway. J Cell Biochem 97 (2005) 1339-1349